Chávez M, Bernal S, Valverde A, Gutierrez M J, Quindós G, Mazuelos E M
Servicio de Microbiología Clínica, Hospital Universitario de Valme, E-41014 Sevilla, Spain.
J Antimicrob Chemother. 1999 Nov;44(5):697-700. doi: 10.1093/jac/44.5.697.
In this report we compare the activity of two new antifungal agents, voriconazole (UK-109,496) and LY303366 with the activities of other antifungals including fluconazole, itraconazole, 5-fluorocytosine (5FC) and amphotericin B against 219 oral Candida spp. isolates from HIV-infected patients. We used the broth microdilution method following the guidelines of the NCCLS. The in-vitro activity of voriconazole (UK-109,496) (MIC(90) 0.12 mg/L) and LY303366 (CMI(90) 0.25 mg/L) against clinical isolates of Candida spp. was excellent and comparable with that of amphotericin B (MIC(90) 0.5 mg/L), and better than those of fluconazole (MIC(90) > or = 64 mg/L), itraconazole (MIC(90) 4 mg/L) and 5FC (MIC(90) 1 mg/L).
在本报告中，我们比较了两种新型抗真菌药物伏立康唑（UK-109,496）和LY303366与其他抗真菌药物（包括氟康唑、伊曲康唑、5-氟胞嘧啶（5FC）和两性霉素B）对219株来自HIV感染患者的口腔念珠菌属分离株的活性。我们按照美国国家临床实验室标准委员会（NCCLS）的指南采用肉汤微量稀释法。伏立康唑（UK-109,496）（MIC90为0.12 mg/L）和LY303366（CMI90为0.25 mg/L）对念珠菌属临床分离株的体外活性极佳，与两性霉素B（MIC90为0.5 mg/L）相当，且优于氟康唑（MIC90≥64 mg/L）、伊曲康唑（MIC90为4 mg/L）和5FC（MIC90为1 mg/L）。
